The aim of the study was to evaluate the outcome of unrelated bone marrow donor (UBMD) searches initiated for 174 children between 1986 and 1997. Seven patients were registered twice so that a total of 181 UBMD searches took place. At the time of registration, patients suffered from hematological malignancies (n = 121), non-malignant hemopathies (n = 26) and inborn errors (n = 34). Forty-five of the patients (26%) were given transplants from unrelated donors of whom 26 (58%) were HLA-mismatched transplants. Our strategy accepted HLA mismatches at the time of donor selection, using Thymoglobuline as part of the conditioning regimen. Of the 45 patients given unrelated donor transplants, overall survival was 60% at 3 years and concerned 27 patients of whom 14 were from HLAmismatched donors. Disease-free survival for hematological malignancies was 65% in HLA-matched transplants and 50% in HLA-mismatched transplants. For some patients (16%) urgency led us to use alternative options: non-identical related donor (n = 14), autograft (n = 10), related cord blood transplant (n = 4). For others, UBMD searches were stopped because of favorable evolution (n = 29), death (n = 24), disease progression (n = 22) or other reasons (n = 21). By the end of the follow-up period, 88 patients had died (50%), 75 (43%) are currently alive with or without being transplanted of whom eight are still having active searches and 11 are no longer contactable. In conclusion, in severe disease in children, an immediate transplant from a partially matched donor might be preferable to a prolonged search for a full match. Consequently, this strategy increases the number of patients for whom a suitable donor can be found. We have chosen this option in order not to delay BMT; in so doing we have obtained encouraging results which include high overall survival, low incidence of acute GVHD grade III-IV and low percentage of relapse even in mismatched pairs. Bone Marrow Transplantation (2000) 26, 31-43.
Allogeneic transplants from HLA genotypically identical siblings are now carried out with success as a potentially curative treatment for patients with hematological diseases, non-malignant hemopathies and inborn errors. However, for the 70% of patients who lack an HLA compatible family member, it is now possible to find a potential unrelated bone marrow donor (UBMD) among more than 5 million volunteers world wide. [1] [2] [3] Several studies have shown that an HLA-matched or partially matched UBMD can be used in bone marrow transplantation (BMT) therapy for the various diseases mentioned. [4] [5] [6] [7] [8] [9] [10] Nevertheless, unrelated BMTs are associated with an increased risk of non-engraftment, graft-versus-host disease (GVHD) and toxicity. However, with experience, clinical outcomes are improving. It is also now customary for national and international registries to offer unrelated donor searches to all patients enrolled in a BMT program, especially high risk patients. The aim of this study was to describe the process of UBMD searches carried out in our center over 12 years in 174 children, and to describe the outcome of these patients whether transplanted or not. Such an approach has been neglected to date in the literature.
Patients and methods

Population
From January 1986 to December 1997, 174 children (88 male and 86 female) aged from 1 month to 18 years (median: 6.6 years), who lacked HLA-identical siblings were entered on the waiting list of unrelated bone marrow donor registries in order to identify a suitable donor. They all suffered from hematological diseases, malignant or nonmalignant, or from inborn errors. Their disease and disease status or previous graft failure led to their enrolment in an unrelated bone marrow transplant search procedure. Four patients were primarily autografted. Seven patients were registered twice. Patients' diagnoses and disease stage at the time of registration are described in Table 1 . 
Search registration and strategy for searching
Registration of patients on UBMD registry lists was always decided after local consensus. A deadline for donor location, generally 3 months, was established. The clinical status of the patient and disease evolution was re-evaluated each week. The first patient registration was made on 7 January 1986 and the number of requests for UBMD gradually increased following this and eventually became routine. The strategy currently applied is detailed in Figure 1 . The initial search scans for HLA-A, B, DR phenotypically identical donors and also for partially compatible donors especially for those patients at high risk of disease progression. The rationale for this approach stems from our own experience and from other studies of haploidentical related transplants with one HLA-A, B or DR locus mismatch. The latter studies reported results similar to those observed after HLA genotypically identical transplantation. [11] [12] [13] [14] [15] The Bone Marrow Donor World wide (BMDW) database containing the HLA phenotypes and number of donors per phenotype from bone marrow donor registries is consulted as a tool, giving an immediate future direction of searches for each patient. 16 
Patient/donor HLA typing
Patients were always genotyped at time of the family investigation for a related donor. HLA data on recipients and donors became more complete as the technical progress of tissue typing evolved. There were three distinct steps of HLA typing. HLA class I (A and B loci) and class II (DR and DQ loci) typing were initially performed serologically by standard two stage complement-dependent microlymphocytotoxicity testing. Local sera were used. T and B cells were separated on nylon-wool columns. 17 The development of DNA-based allele level typing for class II started at the end of 1991, and was the second step and thus, patients and donors were typed by serology for class I and molecular biology for class II. In 1996, the third step was the introduction of DNA typing for HLA class I alleles, first for loci A and C. Serological typing for the C locus had not been previously carried out. Later on, DNA typing was extended to HLA-B alleles. Currently, all HLA alleles for class I and II are routinely determined. We performed DNA typing of alleles at nine polymorphic loci: alleles at the HLA-A‫,ء‬ -B‫,ء‬ -Cw‫,ء‬ -DRB1‫,ء‬ -B3‫,ء‬ -B4‫,ء‬ -B5‫,ء‬ -DQB1‫ء‬ and -DPB1‫ء‬ loci are identified by polymerase chain reaction (PCR) with sequence specific oligonucleotide probes 18, 19 or with PCR sequence specific primers issued from the 11th and 12th workshop, 20, 21 as well as from commercial kits. High resolution typing for class I and/or class II alleles was retrospectively completed for all recipient/donor pairs who had been transplanted between 1989 and 1996. Rare alleles found in the retrospective study were sequenced after cloning by using either manual sequencing or automated fluorescence methods. [22] [23] [24] All alleles from class I and class II which have been published in the nomenclature for factors of the HLA system were studied. 25 The mixed lymphocyte culture (MLC) was carried out for each patient/donor pair and used as a tool for donor selection. Results of MLC, expressed as a percent of stabilized relative response calculated (% SRR), 26 were taken into account because of the significant association with acute GVHD. Cytotoxic T-lymphocyte precursor (CTLp) assays were not undertaken.
Informed consent
The risks of the treatment protocols were fully explained to parents and older children. Informed consent and written agreement were obtained from all parents for patients eligible for a marrow transplant protocol.
Supportive care
All patients had indwelling central venous catheters and were nursed in a sterile isolator or less frequently in laminar air flow. Sterile care and oral and gut decontamination were given. All received intravenous immunoglobulins. fractionated total body irradiation (FTBI) 12 g, six fractions in 3 days followed by chemotherapy 27 or chemotherapy alone. For GVHD prophylaxis, patients received a combination of cyclosporine (CsA) and methotrexate (MTX). Cyclosporine was given at a dose of 5 mg/kg/day beginning on day −1 for 5 days followed by intravenous cyclosporine at 3 mg/kg/day, converted to 12.5 mg/kg/day orally when oral medication could be tolerated. Intravenous methotrexate was administrated at a dose of 15 mg/m 2 on day 1 and at 10 mg/m 2 on days 3, 6 and 11. Thymoglobuline (ImtixSangstat, Lyon, France) was administered to patients receiving unrelated BMT both as prophylaxis for rejection and for GVHD. In most cases it was given prior to transplant to obtain partial in vivo T cell depletion, at a total dose of 20 mg/kg on days −7, −5, −3 and −1. Donor marrow was not T cell-depleted before infusion except in three patients who received cells depleted with rabbit complement and anti-CD2, CD5, CD7 monoclonal antibodies.
Conditioning regimens
Haploidentical BMT: Fourteen patients were transplanted from haploidentical donors, with bone marrow in 12 cases and peripheral blood stem cells in two cases. 28 Conditioning was appropriate to the underlying disease and in four cases was carried out following the Trigg protocol C: VP 16, aracytine, cyclophosphamide, fractionated TBI 12 Gy and corticosteroids plus Thymoglobuline as GVHD prophylaxis without cyclosporine or methotrexate 29 and marrow T cell depletion before infusion. Four patients were conditioned according to the Fischer protocol. 30 For children Ͼ2 years, conditioning consisted of FTBI 12 Gy, aracytine and melphalan. Children Ͻ2 years generally received BU CY.
Bone Marrow Transplantation
Autologous transplantation: Autografted patients suffering from acute hematological malignancies were conditioned with FTBI, aracytine, melphalan (TAM 24 g/m 2 or TAM 18 g/m 2 ) 31 plus CsA in six cases with the aim of inducing an autoGVH effect. 32 Two patients with CML received the SFGM protocol: busulfan and high-dose melphalan (HDM) according to Reiffers protocol. 33 Patients received purged BMT in seven of 10 cases.
Assessment of BMT outcome
Engraftment was defined as the time when the peripheral blood neutrophil count exceeded 0.5 × 10 9 /l for 3 consecutive days. Engraftment was studied by Southern analysis of DNA hypervariable regions (minisatellite probes monolocus MS31 and MS43) and/or by means of HLA typing in mismatched pairs and/or chromosomal studies. GVHD was graded according to Glucksberg et al 34 and confirmed by appropriate histological studies.
Primary graft failure was defined as the lack of myeloid engraftment in patients surviving in remission for at least 28 days after transplantation.
Statistics
All patients registered on the waiting list of unrelated bone marrow donor registries from 7 January 1986 to 31 December 1997 and the 45 consecutive unrelated BMT performed during this period were included in this study.
The reported outcomes are as of 31 December 1998 and there was at least 1 year follow-up data available for all survivors. The rate of overall survival and disease-free survival was calculated by the Kaplan-Meier method and the log-rank test was used to compare the probabilities of survival.
Results
At present, searches remain active for eight patients. For others, searches were stopped. The mean duration of the searches was 14.9 months (median: 8.8 months, range: 9 days to 85 months). The causes of cancellation and percentage are detailed in Table 2 . The population of children on whom searches for donors was made can be divided into two groups: transplanted patients whatever the transplant procedure (n = 77; three patients being transplanted twice, 45%) and patients for whom searches have been stopped without transplantation whatever the reason (n = 96, 56%).
Outcome for transplanted patients
Unrelated BMT: Unrelated bone marrow donors were recruited for 45 patients successively transplanted from May 1989 to June 1997. They suffered from hematological malignancies (n = 25, 56%), non-malignant hemopathies (n = 6, 13%) or inborn errors (n = 14, 31%). Characteristics of the patients are detailed in Table 3 . Infusion of marrow from a UBMD was the second transplantation procedure for four patients. One patient with AML previously autografted in CR1 received UBMT in aplasia following intensive induction chemotherapy for a second relapse. Three patients (Hurler's disease, aplastic anemia, familial lymphohistiocytosis (FLH)) received UBMT after graft failure from an HLA-mismatched father. Three patients were transplanted twice with the same UBMD: two ALL, one Fanconi's anemia (FA).
The median total nucleated cell dose infused per kg was 5.15 × 10 8 (range: 1.00-9.56). Donors originated from France (23 patients, 51%), Europe (13 patients, 29%) and USA (9 patients, 20%). Twenty-six of the 45 pairs were HLA-mismatched; four of these mismatches were unknown at time of BMT (Table 4) .
Thirty-eight of the 45 patients (84%) engrafted. The median time to neutrophil engraftment was 22 days (range 12-41 days). Engraftment was not evaluable in four cases, because of early death in three cases, and non-documented engraftment before death in one patient who died on day 27. Three patients failed to engraft. One patient with AML died on day 44 from liver and renal veno-occlusive disease (VOD) after prolonged hemodialysis. Two patients with Hurler's disease are alive after failure with T-depleted UBMD BMTs, matched in one case, mismatched in the other.
Three of the 38 patients who originally engrafted had graft rejection (8%). Two of these three had FA and rejected at 91 and 48 days. In the first case, a second BMT from the same unrelated donor was performed but the patient died of septicemia after a second rejection. The second patient died on day 256 of invasive aspergillosis without being retransplanted. The third patient who had graft rejection had ALL and rejected 32 days after treatment Table 4 Forty-five match (M) mismatch (MM) HLA pairing at time of BMT and retrospectively determined
Step 1 Step 2 Step with ribavirin for adenovirus infection; he died of VOD on day 39.
Acute GVHD was present in 17 of the 38 patients who engrafted (44.7%): grade I (n = 7, 41%), grade II (n = 4, 23.5%), grade III (n = 4, 23.5%) or grade IV (n = 2, 12%) aGVHD. Four out of 16 patients (23.5%) evolved to chronic GVHD, limited in two cases and cured, extensive in the two other cases: one cured, one controlled.
Relapse of malignant disease occurred in six of 21 patients with sustained engraftment (28.5%) at a median time of 430 days after BMT (range 153-957 days). One patient with AML5 transplanted in the fourth blastic phase progressed rapidly after engraftment and died on day 45. One ALL t(9; 22) relapsed 256 days post BMT and died of disease progression. Two other patients with ALL benefitted from a second BMT with the same UBMD and are currently in complete remission (follow-up: 84 months for ALL in CR3, 31 months for ALL t(4; 11) in CR2). An infusion of donor leukocytes (DLI) was administered to the two remaining patients, both in complete remission after intensified induction chemotherapy. However, one ALL relapsed 7 months later and died of disease progression and the second AML t(9;22) died of septicemia 6 months after DLI while in third remission.
For lysosomal storage diseases, mixed (n = 2) or full (n = 6) chimerism was obtained at a median follow-up of 29 months (range 18-108 months) with a functional graft. The three patients with FLH are clinically and immunologically perfect without late effects. A patient suffering from Wiskott-Aldrich syndrome had a history of two EBVrelated lymphoproliferative diseases before BMT. He had severe aGVHD which necessitated high-dose steroids, Thymoglobuline and prolonged anti-IL2 receptor treatment. He remains in complete remission after having received marrow from an EBV-positive donor.
Transplant-related mortality occurred in 12 patients (26%). Conditioning regimen toxicity was the cause in two cases; one patient with aplastic anemia conditioned with TBI, CY and Thymoglobuline developed toxic epidermal necrolysis (Lyell syndrome) which began before transplantation; one patient with RAEBt transplanted in blastic phase had an acral dermatitis syndrome due to aracytine and died Bone Marrow Transplantation in the intensive care unit on day 19 from multiple organ failure.
Two patients died from VOD in the intensive care unit on days 44 and 39 post transplant. One sudden death occurred after hemorrhage from a duodenal ulcer on day 13. One patient died of aGVHD grade IV. One patient with aGVHD grade III received high-dose corticosteroids and a second course of Thymoglobuline and died on day 66 with neurological complications, repeated seizures and a cerebral mass without systemic infection. One patient died of multiple organ failure on day 27.
Death due to proven infection occurred in three patients: the first died from interstitial pneumonitis due to CMV after prolonged Thymoglobuline treatment following the Trigg protocol; the second died on day 125 from Pseudomonas aeruginosa; the third died on day 151 with multiple organ failure. He received DLI successfully for adenovirus infection but late acute renal failure due to cyclosporin occurred, which was treated by prolonged hemodialysis. He developed severe varicella in the intensive care unit and died with intractable hemorrhagic cystitis. Myeloid engraftment occurred without immunological reconstitution. A patient with CML in prolonged chronic phase received 15 doses of Thymoglobuline post BMT following the Trigg protocol. He presented soon after transplant with an overwhelming EBV-induced proliferative syndrome and died on day 56. Other causes of death have been mentioned previously (two patients with FA and four out of six relapsed patients).
The overall actuarial survival is 60% at 3 years, 68% at 3 years for the full matched UBMT, 58% at 3 years for the one to four mismatched UBMT (log rank 0.29) (Figure 2 ). Twenty-seven out of 45 patients survived (six ALL, two AML, three MDS, one JMML, one CML, one AA, seven Hurler's disease, one Hunter's disease, one mucolipidosis, three FLH, one Wiskott-Aldrich syndrome) of whom 14 (52%) were HLA-mismatched. The median follow-up is 52 months, (range: 18-111 months). For hematological malignancies, the relapse-free survival at 3 years with strict HLA identity at the allelic level for A‫,ء‬ B‫,ء‬ Cw‫,ء‬ DRB1‫,ء‬ DQB1‫ء‬ (not taking into account DPB1‫)ء‬ is 65% (n = 12)
Bone Marrow Transplantation and 50% in HLA-mismatched pairing (n = 9) (P = 0.70) (Figure 3 ).
Non-identical familial BMT:
In 14 patients, the absence of UBMD location and the very poor prognosis of the underlying disease led us to proceed with BMT from haploidentical or familial mismatched donors. They suffered from severe hematological diseases (n = 8), familial lymphohistiocytosis (n = 3), immune deficiencies (n =2) and Hurler's disease (n = 1). Twelve patients died (86%). Two of three patients with graft failure are currently alive after being transplanted both from mismatched UBMD (follow-up : 23 months for FLH; 12 months for Hurler's disease). For these two patients, searches were initiated as soon as the notification of graft failure was received and UBMDs were rapidly identified.
Related cord blood transplant: For four patients (two ALL, two Hurler's disease), after waiting for a median time of 34 months for a possible UBMD, we decided to proceed to a related CBSC transplant: three were HLA-mismatched. One patient with Hurler's disease is currently alive after graft failure and autologous reconstitution. The three others have died (75%) due to cerebral hematoma, prolonged aplasia and invasive aspergillosis, respectively, after full engraftment.
Autograft:
The 10 autografted patients suffered from severe hematological malignancies. Seven patients had ALL: two VHR ALL in CR1 both after induction failure (one t(9;22)); four ALL in CR2 (one T cell ALL, one t(4;11)); one ALL in CR3. Two patients had CML in first chronic phase. One patient suffered from T-NHL in CR2 at the time of autografting. Patients were registered on the waiting list for 111 days (median) (range: 30-575 days) when they were enrolled for autografting. Four of these 10 patients are alive (40%) in complete remission with a median follow-up of 85 months: one ALL T CR1 induction failure (followup: 63 months), one T-NHL CR2 (108 months), one ALL CR3 (42 months), one CML (108 months). The two surviving patients with ALL were given cyclosporine.
Other patient outcomes
Favorable evolution: When searches were stopped because of favorable disease status, patient outcome was good in 24/29 cases (83%). For these 24 patients the median followup without relapse is 85 months (range: 18-118 months) since they were removed from the donor request list. At the time of registration they suffered from AA (n = 4), FA (n = 2), ALL (n = 17), lymphoma (n = 1), AML (n = 1), MDS (n = 3), CML (n = 1). One or more HLA compatible donors was identified for seven of these patients but in the light of their favorable clinical situation, it was decided not to proceed immediately to BMT. In five out of 29 patients, disease progression occurred. Two patients are currently alive in CR after undergoing an autograft (one lymphoma, one secondary T ALL after lymphoma) (follow-up: 85 and 132 months). One patient with ALL (with a low blast count after third relapse) was transplanted from a genotypically identical sibling born in the meantime, with success (follow-up: 85 months). One patient with RAEBt relapsed 27 months after the search was stopped. He was re-registered and transplanted with unrelated cord blood identified immediately, with success (follow-up: 54 months). The fifth patient with AML died of relapse after a CR of 7 years, a second UBMD search was started, but failed to find a suitable donor before disease evolution rendered transplantation impossible.
Death: Twenty-four patients died during the UBMD search process. In 19 cases, a suitable donor was not identified before death. In five cases, a suitable donor was located too late and transplantation was contraindicated because of disease progression.
Disease progression: All of the 22 patients whose donor search was cancelled because of disease progression died except for one with AML M5 who achieved CR after an autograft (follow-up: 30 months). Finally, when searches were stopped because of disease progression or clinical status, 95.5% of patients died at a median interval of 62 days (range: 9-174 days) after search cessation.
Other reasons for cancellation: Twenty-one patients (13%) were removed from registries for reasons other than clinical causes or enrolment in the BMT procedure (Table 2) .
For eight patients, their file was transferred due to family relocation and searches were relayed by another center. Three foreign patients returned to their country of origin (two Italian and one Algerian).
Searches were stopped at the parents' request in five cases: for two patients, the parents requested cancellation of UBMD; in two cases, the parents adopted complementary medicine and a UBMD was identified for one of them; in a case of Hurler's disease, the mother of the patient was opposed to BMT because of religious convictions.
In two cases, searches were stopped after a team decision because the patient's condition was considered to be a contraindication to BMT. One patient with RAEBt had psychological problems which contraindicated BMT, and in the case of one patient with Hurler's disease, late diagnosis and disease severity were unfavorable for BMT outcome.
Two patients responded to treatments other than BMT: one patient with Kossman disease and one patient with atypical osteopetrosis. Contact was lost with one patient.
Overview
The global outcome of patients is shown in Figure 4 . Among the 174 patients registered, 88 have died (40%), 39 of whom (44%) died after BMT, whatever the transplant procedure. Apart from five patients for whom an identical UBMD was identified too late for BMT, 49 patients died before a suitable UBMD could be found. Seventy-five patients (43%) are currently alive, 35 (47%) post BMT, whatever the marrow source. Eight searches are currently in progress. For two of these eight patients, an UBMD has been recruited and BMT is planned in a few weeks. Suitable UBMDs (HLA and cellular testing performed) have been located for seven patients in prolonged CR or with Bone Marrow Transplantation stable disease which prompted the discontinuation of searches: two FA, two ALL in CR2, two MDS, one CML. Contact has been lost with 11 patients (7%).
Donor search progression and evolution with time
In order to evaluate evolution of UBMD searches for our patients, we analyzed a population of 166 children for whom UBMD searches have now reached their conclusion. Sixty-six percent (n = 109) of patients were registered on European volunteer donor registries and 43% (n = 71) on the US National Marrow Donor Program (NMDP). The mean number of donors per patient selected as being HLA-A, -B, -DR serologically identical and requested for testing was 3.2 (median 2, range 1-21). For 48 patients (30%), no potential donor was located although one HLA class I mismatch was accepted in certain cases. Among the 33 children who had only one potential matched donor identified, 11 (33%) were transplanted from this donor. The number of patients who achieve transplantation rises with the number of HLA-A, -B, -DR identical donors tested. Thirty-three per cent of patients who had between two and five matched donors were transplanted, 41% of patients with between six to 10 potential donors identified, and 62% of those with more than 10 potential matched donors (range 12-21) identified.
When the whole group of 166 patients was subdivided into three time periods, the evolution and progress of searching is well illustrated ( Table 5 ). The first period (1986) (1987) (1988) (1989) (1990) (1991) corresponds to the development of UBMD registries world wide and recipient/donor HLA pairing by serology. During the second period (1992-1995), DNA typing for class II alleles was used as a routine technique and a new strategy in search management was started. Then, during the final period (1996-1997), molecular testing was extended to class I alleles at the time of donor selection and the effects of the more efficient procedure initiated in 1993 are visible.
Discussion
Unrelated bone marrow transplantation is now well established and its feasibility has been demonstrated. 36, 37 This has necessitated development of large national registries of HLA-typed volunteers providing patients with the possibility of finding the donor that they lack in their family. We started UBMD searches for 174 children who were in such a situation, and 45 (26%) were transplanted from selected UBMDs. Forty-nine patients died before unrelated donors could be found (28%). Thirty-nine patients died after transplantation (22%). It must be pointed out that whatever the transplant procedure, disease evolution would also certainly have proven fatal. Because the timing of transplant in relation to disease phase or stage seems to correlate with the global outcome of BMT, choosing the proper indication is very important. Retrospectively, interrogation of registries for the 24 patients who had favorable disease evolution did not seem appropriate despite their classification as high risk at the time of registration. This emphasises the difficulties we had estimating disease 
Table 5
Donor search evolution in time 1986-1991 1992-1995 1996-1997 1986-1997 evolution even for high-risk patients. For patients with severe hematological malignancies, criteria for considering them for an unrelated BMT are established and followed. 38 In a few situations, we initiated UBMD searches for patients with ALL at the time of relapse (1st relapse in 12 cases, 2nd in four cases) in order to save time in the search process and with the hope of obtaining a complete remission. Four out of these 16 patients were transplanted in CR from a UBMD. It seems important to define the upper time limit of searches and to discuss other alternative therapies, if the period is short or if a donor has not been traced. Search management must remain active with constant re-evaluation of clinical data in order to minimise delay in donor location, with the aim of transplanting as soon as possible. Even if finding a UBMD is a challenge beset by inevitable obstacles such as donor withdrawal or unavailability and incorrect HLA typing, 39 we should emphasise the evolution and progress in efficiency of world wide registries. In more than 10 years, we have experienced their effectiveness with increased donor recruitment, including representation of minorities. The methods for initiating and monitoring donor searches for our patients have improved. Better evaluation of inclusion criteria as well as the aforementioned progress has resulted in fewer patients being registered but more being transplanted and this has been confirmed in the course of 1998 with 19 searches initiated and 17 UBMTs performed ( Figure 5 ). During the first period (1986-1991) ( Table 5 ), 15% of the registered patients were transplanted vs 32% during the second period (1992) (1993) (1994) (1995) and 58% for the third period (1996) (1997) . The interval between search initiation and donor recruitment has radically decreased from a median of 7.8 months (1st period) to 2.2 months (2nd period). Currently, donors are recruited a median of 1.6 months after the beginning of the search.
Period
The waiting time is nowadays radically reduced for most patients but constraints associated with time-consuming HLA typing processes must not be allowed to increase the interval between search and transplantation. The impact of high resolution HLA typing for class I and class II alleles on definition of a match is highly rewarding. It is now possible to carry out donor searches in almost 'real time' using DNA technology as a tool for donor selection. However, we should be aware of the unfortunate consequences of patients being excluded from transplantation simply because the matching criteria are changed by new technology. As others, 37 we have performed BMTs with unknown mismatches or underestimation of the number of alleles mismatched at time of transplant because patient and donor pairs were serologically defined. During the initial time period, when the first step of HLA pairing was serologically defined for both recipient and donor, transplantation with either HLA-A, -B or -DQ antigen mismatches was performed in five of 10 pairs (50%) ( Table 4) . Retrospective high resolution typing for class I and class II alleles revealed only one unknown mismatched pair at time of BMT, but the numbers of HLA disparities for each initial mismatched pair increased, particularly for HLA-C alleles (Table 4) . At present, five out of 10 patients are alive (50%).
In fact, the difficulty in obtaining one or more HLA identical donors for certain patients with unusual phenotypes or rare alleles and/or the urgency to proceed to BMT led us to accept donors with one HLA-mismatch for class I antigens. Taking into account the results obtained with these first mismatched UBMTs, we decided to deliberately initiate donor searches with one HLA class I mismatch for patients for whom searches for an exact match were unsuccessful.
The effect of mismatching for one HLA locus was reported by Beatty et al 40 in 1993 with 112 patients under 36 years suffering from hematological malignancies. Fortytwo had a 'minor' disparity at one HLA locus. These patients received unmodified non-T cell-depleted donor marrow cells. The probability of survival for good risk patients was similar at 1.5 years for both matched and parBone Marrow Transplantation tially matched transplants: 51% and 46%, respectively. These results, at least in younger patients, suggested that criteria for choosing UBMDs could include minor mismatches, thus expanding the number of potential donors for each patient.
In the second step of our series, 21 patients underwent BMTs which had been typed by molecular biological techniques, including HLA -DRB1‫ء‬ and -DQB1‫ء‬ typing. Eleven out of 22 pairs were HLA mismatched for one or two antigens (50%) ( Table 4) . Retrospective allelic typings revealed three unknown mismatched pairs and a higher number of mismatches for already known mismatched pairs. Among these 22 transplanted patients, 12 are currently alive (55%).
Balduzzi et al 12 analyzed results of unrelated BMTs performed between April 1985 and April 1993 in 88 children with hematological diseases transplanted with matched (n = 46) or mismatched (n = 42) donors, with HLA DRB1‫ء‬ being defined from the beginning of 1990. Patients received the same conditioning regimen (TBI, CY 120, CsA plus a short course of MTX and T cell non-depleted marrow donor cells). Eighty-two (93%) of 88 patients achieved sustained engraftment. Transplant-related mortality reached 28% and relapse was the primary cause of death. The Kaplan-Meier estimate of disease-free survival at 3 years was 47% for ALL in 1st or 2nd CR. These data showed that marrow transplantation from fully or partially HLA-matched UBMD could be an effective therapy for children with hematological disorders. But how many patients were really matched at that time ? How many mismatches were missed in pairs classified as 'fully' matched? The significance of mismatching on UBMT results reported might be different with a higher degree of class one resolution typing.
Early in 1996, high resolution typing for class I and class II alleles was carried out at the time of BMT for 13 pairs with one to three antigen or allele mismatches in six cases (46%). Ten out of 13 patients are alive (77%) including the six patients transplanted with HLA-mismatched UBMDs. Given the linkage desequilibrium, high resolution typings performed retrospectively on 32 pairs detected a number of associated mismatches but four pairs were really unknown as mismatched pairs at time of BMT. Thus, even if we have new HLA data, the fact remains that 50% of BMTs have been deliberately performed using mismatched donors.
HLA-DRB1 mismatching is associated with a higher risk of aGVHD as well as transplant-related mortality. In consequence, matching DRB1 alleles of donor and recipient decreases the risk of aGVHD and improves survival after BMT. 41 In our study, the selected donors were always HLA DRB1‫ء‬ identical with the recipient except for three patients with HLA-DRB1‫ء‬ 1101/1104 mismatches. In two cases, the presence of ‫4011ء‬ in the recipient while ‫1011ء‬ was present in the donor did not result in cellular proliferation assessed by MLC. Survival of these two patients with absent or low-grade aGVHD led us to now accept DRB1‫ء‬ 1104/1101 mismatches.
In the study of Sierra et al, 42 patients in remission from leukemia at the time of BMT had improved leukemia-free survival and the use of donors with limited HLA mismatches was associated with decreased leukemia relapse. Furthermore, in patients transplanted in remission, increasing marrow cell dose was associated with faster hematological engraftment and immunological recovery as well as a decreased incidence of severe acute GVHD. Transplantation of a marrow cell dose above the median value of 3.65 × 10 8 /kg and its association with transplant-related mortality and leukemia-free survival should be considered. For the 45 UBMTs, we always requested large marrow cell doses, and the median marrow cell dose infused was 5.15 × 10 8 cells/kg. The specified marrow cell dose required should be examined carefully by the harvesting centers while considering the donor/recipient body weight ratio.
In 1997, Pedersdorf et al 43 reported that HLA-C disparity was associated with graft failure after marrow transplantation from UBMDs and that HLA-A and -B mismatches were also found to be risk factors for graft failure. Using high resolution typing of class I and class II alleles, Sasazuki et al 44 found that most patients who received a transplant from an HLA-A, B and DR donor defined by serologic analysis were HLA-mismatched at the alleleic level. Mismatches of HLA-A alleles were an independent risk factor for death and mismatches of HLA-A and HLA-C increased the risk of aGVHD. Furthermore, matching of HLA-C increased the risk of relapse and as a result did not increase the chance of survival. In our study, graft failure or marrow graft rejection associated with HLA class I disparity was not significant as compared to such events for patients transplanted with HLA class I identical donors (Table 6) .
How much matching is necessary? This question, posed by Madrigal 45 may have different answers depending on the underlying disease and the strategy chosen to overcome mismatches. The increased risk of graft failure for hemato- logical malignancies is favorably balanced by the chance of being cured by GVHD and GVL effects of mismatching at class I loci. If the objective is to correct lysosomal storage diseases, we have to decrease graft failure and GVHD effects, since the GVL effect is of no importance. This therapeutic approach is identical for patients with severe hemoglobinopathies or bone marrow failures without myelodysplastic syndrome. 46 The quest for UBMDs with optimal HLA matching depends on the strategy defined and we have to choose between T cell-replete or depleted donor marrow. T cell depletion is an efficient, well recognised method of curing severe combined immunodeficiencies. For hematological diseases, it is associated with an increased risk of graft failure, graft rejection or relapse. The procedure is proposed by Casper et al 11 and Cornish et al 47 with favorable outcome. Recent procedures eliminating T cells of donor origin prevent aGVHD and offer the possibility of T cell add back. We use Thymoglobuline in conditioning regimens to prevent graft rejection, to limit aGVHD and with the hope of limiting transplant-related mortality. Thymoglobuline is usually used as part of the conditioning regimens in patients at high risk of rejection (aplastic anemia), aGVHD in unrelated BMT 48 or in mismatched related donor transplants particularly haploidentical donor/recipient transplants. 49 The use of Thymoglobuline induces in vivo T cell depletion involving both donor T lymphocytes and residual host T lymphocytes resistant to conditioning. Thymoglobuline has potent control on immunoactivation of T cells involved in both graft rejection and aGVHD. In our experience, despite a high degree of HLA mismatching we observed a low incidence of graft failure and an acceptable incidence of aGVHD (Table 7) . In Ringdén's experience, 50 a low incidence of aGVHD was observed with Thymoglobuline. The cumulative incidence of aGVHD II-IV was 23% in recipients transplanted from compatible donors. In contrast to the study from Seattle, the only significant risk factor of aGVHD grade II-IV was fast engraftment Ͼ0.2 × 10 9 WBC/l Ͻ15 days post BMT (35% vs 17% for those having a slower engraftment). In this study of 132 patients, 47 were under the age of 17 years. Incidence of moderate-to-severe aGVHD was lower than previously reported. 10, 51, 52 Almost half the deaths were due to infection. Relapse was a major cause of death in this study, where 54 patients had early diseases (low risk) and 54 more advanced diseases (high risk). However, in our study, relapse incidence is low (six patients, two retransplanted with success).
Despite efforts to increase the size of UBMD registries and to broaden their ethnic diversity, some patients will never be able to find a fully HLA matched donor. Knowing that the period when the patient can be transplanted with a good expectation of success is limited, we should evaluate the risks and benefits and then try to optimize the chances of a good result when selecting the donor. Other factors that affect the outcome of unrelated BMT must be borne in mind when selecting a donor (gender, age, CMV and EBV status), 45 and thus selecting a fully matched donor is not necessarily the optimal choice.
Lastly, 19/45 unrelated BMTs were performed with strict HLA identity (DP excluded) (42%) but 26/45 had one to four HLA allele or antigen mismatches (58%). Since the beginning of our experience, transplant outcome has been encouraging despite absence of the most stringent matching, thus requiring the addition of Thymoglobuline to the conditioning regimen. Currently, in our institution, even if transplants are always performed using the optimum HLAcompatible donor, our search strategy aims to carry out a BMT procedure in under 3 months for children who could not otherwise receive a transplant. In the absence of such a donor, BMTs are performed using an HLA-mismatched donor, this being preferable to alternatives such as cord blood transplant, haploidentical familial transplant or autograft.
This 12 years' experience and the good patient outcome has influenced our practice of unrelated bone marrow transplantation leading us to balance the timing of the BMT with the matching available. Unrelated BMT represents a lifesaving therapy for children suffering from hematological malignancies or inborn errors and HLA mismatches should not necessarily lead to cancellation of transplant procedures.
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